Patent · US Active

3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke

US11339124B2 · kind B2 · utility

1Cited by

0References

7Claims

0Family size

Assignees

Inventors

Peter Vandenabeele · Sint-Amandsberg, BE
Tom Vanden Berghe · Haasdonk, BE
Koen Augustyns · Holsbeek, BE
Sam Hofmans · Willebroek, BE
Pieter Van Der Veken · Wilrijk, BE
Lars Devisscher · Turnhout, BE

Key dates

Filing date	Feb 5, 2019
Grant date	May 24, 2022
Priority date	—
Expiry date	Jun 29, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C311/17
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.